EPICEPT ANNOUNCES PRICING OF PUBLIC OFFERING

EPICEPT ANNOUNCES PRICING OF PUBLIC OFFERING

TARRYTOWN, N.Y. (June 19, 2009) - EpiCept Corporation (Nasdaq and OMX Nordic
Exchange:  EPCT) announced today that it entered into definitive agreements for
the purchase of approximately 12.0 million shares of its common stock at $.80
per share and two-and-one-half-year warrants to purchase up to approximately 4.2
million shares of common stock at an exercise price of $.90 per share
exercisable beginning December 19, 2009. The offering is expected to close on or
about June 23, 2009, subject to the satisfaction of customary closing
conditions.  EpiCept will receive approximately $8.9 million in net proceeds
from the offering.  

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.
(Nasdaq: RODM) acted as the exclusive placement agent for the offering. 

Net proceeds from the offering will be used to meet working capital needs and
for general corporate purposes.  EpiCept intends to apply a portion of the net
proceeds to fund certain expenses necessary for the previously announced Named
Patient Program for Ceplene, the filing of applications for marketing approval
of Ceplene in the United States and Canada and to prepare for the commercial
launch of Ceplene in the European Union. The proceeds of this offering together
with existing cash are expected to be sufficient to fund operations into the
second quarter of 2010. 

The proposed public offering is being made pursuant to an effective registration
statement, and may be made only by means of a prospectus and prospectus
supplement. A copy of the prospectus supplement relating to the common stock and
warrants can be obtained from Rodman & Renshaw LLC, 1270 Avenue of the Americas,
New York, NY 10020, or by calling 212-356-0549.

An electronic copy of the prospectus supplement will also be available on the
website of the Securities and Exchange Commission (the “SEC”) at
http://www.sec.gov.

This press release is neither an offer to sell, nor a solicitation of an offer
to buy, nor shall there be any sale of, these securities in any state in which
such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical
products for the treatment of cancer and pain.  The Company's lead product is
Ceplene®, which has been granted full marketing authorization by the European
Commission for the remission maintenance and prevention of relapse in adult
patients with Acute Myeloid Leukemia in first remission.  The Company has two
oncology drug candidates currently in clinical development that were discovered
using in-house technology and have been shown to act as vascular disruption
agents in a variety of solid tumors.  The Company's pain portfolio includes
EpiCeptTM NP-1, a prescription topical analgesic cream in late-stage clinical
development designed to provide effective long-term relief of pain associated
with peripheral neuropathies.

Forward-Looking Statements 

This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include:  the risk that the proposed offering will not be completed, the risk
that we will not have sufficient authorized shares of stock to raise equity
capital, the risks associated with the adequacy of our existing cash resources
and our ability to continue as a going concern, the risks associated with our
ability to continue to meet our obligations under our existing debt agreements,
the risk that our securities may be delisted by The Nasdaq Capital Market or the
OMX Nordic Exchange and that any appeal of the delisting determination may not
be successful, the risk that Ceplene® will not be launched in Europe in the
second half of 2009 or achieve significant commercial success, the risk that we
are unable to find a suitable marketing partner for Ceplene® on attractive
terms, a timely basis or at all, the risk that any required post-approval
clinical study for Ceplene® will not be successful, the risk that we will not be
able to maintain our final regulatory approval or marketing authorization for
Ceplene®, the risk that Ceplene® will not receive regulatory approval or
marketing authorization in the United States or Canada, the risk that Myriad's
development of Azixa™ will not be successful, the risk that Azixa™ will not
receive regulatory approval or achieve significant commercial success, the risk
that we will not receive any significant payments under our agreement with
Myriad, the risk that the development of our other apoptosis product candidates
will not be successful, the risk that we will not be able to find a buyer for
our ASAP technology, the risk that clinical trials for EpiCeptTM NP-1 or
crinobulin will not be successful, the risk that EpiCeptTM NP-1 or crinobulin
will not receive regulatory approval or achieve significant commercial success,
the risk that we will not be able to find a partner to help conduct the Phase
III trials for EpiCeptTM NP-1 on attractive terms, a timely basis or at all, the
risk that our other product candidates that appeared promising in early research
and clinical trials do not demonstrate safety and/or efficacy in larger-scale or
later stage clinical trials, the risk that we will not obtain approval to market
any of our product candidates, the risks associated with dependence upon key
personnel, the risks associated with reliance on collaborative partners and
others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and uncertainties
associated with our scientific research, product development, clinical trials
and regulatory approval process; our history of operating losses since our
inception; the highly competitive nature of our business; risks associated with
litigation; and risks associated with our ability to protect our intellectual
property.  These factors and other material risks are more fully discussed in
our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and
other filings with the U.S. Securities and Exchange Commission. You are urged to
carefully review and consider the disclosures found in our filings which are
available at www.sec.gov or at www.epicept.com. You are cautioned not to place
undue reliance on any forward-looking statements, any of which could turn out to
be wrong due to inaccurate assumptions, unknown risks or uncertainties or other
risk factors.

###
EPCT-GEN
*Azixa is a registered trademark of Myriad Genetics, Inc.

EpiCept Corporation:
777 Old Saw Mill River Road
Tarrytown, NY 10591
Robert W. Cook
(914) 606-3500
investor@epicept.com 
or
Media:
Feinstein Kean Healthcare
Greg Kelley
(617) 577-8110
gregory.kelley@fkhealth.com 	
or
Investors:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com 
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com